Kynostatin 272 (BioDeep_00001028534)
代谢物信息卡片
化学式: C33H41N5O6S2 (667.2498126)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C)NC(=O)C1CSCN1C(=O)C(C(CC2=CC=CC=C2)NC(=O)C(CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O
InChI: InChI=1S/C33H41N5O6S2/c1-33(2,3)37-31(42)26-19-46-20-38(26)32(43)29(40)24(15-21-9-6-5-7-10-21)36-30(41)25(18-45-4)35-28(39)17-44-27-12-8-11-22-16-34-14-13-23(22)27/h5-14,16,24-26,29,40H,15,17-20H2,1-4H3,(H,35,39)(H,36,41)(H,37,42)/t24-,25-,26-,29-/m0/s1
描述信息
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Koushi Hidaka, Tooru Kimura, Rajesh Sankaranarayanan, Jun Wang, Keith F McDaniel, Dale J Kempf, Masanori Kameoka, Motoyasu Adachi, Ryota Kuroki, Jeffrey-Tri Nguyen, Yoshio Hayashi, Yoshiaki Kiso. Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.
Journal of medicinal chemistry.
2018 06; 61(12):5138-5153. doi:
10.1021/acs.jmedchem.7b01709. [PMID: 29852069] - Misa Ishimatsu, Hajime Suzuki, Hisashi Akiyama, Tomoyuki Miura, Masanori Hayami, Eiji Ido. Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors.
Microbes and infection.
2007 Apr; 9(4):475-82. doi:
10.1016/j.micinf.2007.01.005. [PMID: 17350308] - D R Churchill, P M Slade, M Youle, B G Gazzard, J N Weber. A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection.
The Journal of antimicrobial chemotherapy.
2001 Mar; 47(3):353-5. doi:
10.1093/jac/47.3.353. [PMID: 11222570] - V Hawkins, Q Shen, C C Chiueh. Kynostatin and 17beta-estradiol prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease.
Journal of biomedical science.
1999 Nov; 6(6):433-8. doi:
10.1007/bf02253675. [PMID: 10545779] - T Mimoto, R Kato, H Takaku, S Nojima, K Terashima, S Misawa, T Fukazawa, T Ueno, H Sato, M Shintani, Y Kiso, H Hayashi. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Journal of medicinal chemistry.
1999 May; 42(10):1789-802. doi:
10.1021/jm980637h. [PMID: 10346931] - A Kiriyama, T Nishiura, H Yamaji, K Takada. Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor.
Biopharmaceutics & drug disposition.
1999 May; 20(4):199-205. doi:
10.1002/(sici)1099-081x(199905)20:4<199::aid-bdd174>3.0.co;2-4. [PMID: 10440795] - A Kiriyama, T Nishiura, H Yamaji, K Takada. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.
Antimicrobial agents and chemotherapy.
1999 Mar; 43(3):549-56. doi:
10.1128/aac.43.3.549. [PMID: 10049266] - R W Humphrey, K M Wyvill, B Y Nguyen, L E Shay, D R Kohler, S M Steinberg, T Ueno, T Fukasawa, M Shintani, H Hayashi, H Mitsuya, R Yarchoan. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Antiviral research.
1999 Feb; 41(1):21-33. doi:
10.1016/s0166-3542(98)00058-8. [PMID: 10321576] - B U Mueller, B D Anderson, M Q Farley, R Murphy, J Zuckerman, P Jarosinski, K Godwin, C L McCully, H Mitsuya, P A Pizzo, F M Balis. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Antimicrobial agents and chemotherapy.
1998 Jul; 42(7):1815-8. doi:
10.1128/aac.42.7.1815. [PMID: 9661027] - A Kiriyama, T Nishiura, M Ishino, Y Yamamoto, I Ogita, Y Kiso, K Takada. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
Biopharmaceutics & drug disposition.
1996 Dec; 17(9):739-51. doi:
10.1002/(sici)1099-081x(199612)17:9<739::aid-bdd987>3.0.co;2-0. [PMID: 8968527] - A Kiriyama, M Sugahara, Y Yoshikawa, Y Kiso, K Takada. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
Biopharmaceutics & drug disposition.
1996 Mar; 17(2):125-34. doi:
10.1002/(sici)1099-081x(199603)17:2<125::aid-bdd940>3.0.co;2-5. [PMID: 8907719] - M Sugahara, A Kiriyama, Y Hamada, Y Kiso, K Takada. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent.
Biopharmaceutics & drug disposition.
1995 May; 16(4):269-77. doi:
10.1002/bdd.2510160403. [PMID: 7548776] - A Kiriyama, K Fujita, S Takemura, H Kuramoto, Y Kiso, K Takada. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration.
Biopharmaceutics & drug disposition.
1994 Oct; 15(7):617-26. doi:
10.1002/bdd.2510150709. [PMID: 7849237] - S Kageyama, B D Anderson, B L Hoesterey, H Hayashi, Y Kiso, K P Flora, H Mitsuya. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
Antimicrobial agents and chemotherapy.
1994 May; 38(5):1107-11. doi:
10.1128/aac.38.5.1107. [PMID: 8067746] - A Kiriyama, T Mimoto, S Kisanuki, Y Kiso, K Takada. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations.
Biopharmaceutics & drug disposition.
1993 Nov; 14(8):697-707. doi:
10.1002/bdd.2510140806. [PMID: 8305629]